fter preoperative preparation was completed, on the day of surgery, disposable pulmonary nodular localization needle (Ningbo Sonjiecang Biological Technology Co., LTD., Model: SS510-10) was used for the localization of micro hepatocellular carcinoma that could be found by preoperative CT enhancement or MRI. After the micro hepatocellular carcinoma was located under the guidance of CT, and then the patient was sent to the operating room. During the operation, the lesion was removed according to the tail line of the positioning needle and the position of the positioning needle.

After preoperative preparation was completed, on the day of surgery, disposable pulmonary nodular localization needle (Ningbo Sonjiecang Biological Technology Co., LTD., Model: SS510-10) was used for the localization of micro hepatocellular carcinoma that could be found by preoperative CT enhancement or MRI. After the micro hepatocellular carcinoma was located under the guidance of CT, and then the patient was sent to the operating room. During the operation, the lesion was removed according to the tail line of the positioning needle and the position of the positioning needle.

CT-guided localization for micro hepatocellular carcinoma before surgical resection

Guo-Qing Jiang, MD

Dou-Sheng Bai, MD

Tian-Ming Gao, MD

This study aims to identify inherited genetic variants and somatic mutations associated with the progression of advanced Metabolic Dysfunction-Associated Steatotic Liver Disease MASLD.The research utilizes two distinct and extensively characterized cohorts for Whole-Genome Sequencing WGS analysis:

* MASLD Cohort: Consists of 800 patients whose peripheral blood will undergo WGS at 20x coverage.
* Metabolic Controls} Cohort: Comprises 2000 individuals matched for sex and metabolic risk factors who meet at least two criteria for metabolic syndrome but are free of MASLD. Their peripheral blood DNA will also be sequenced.

The focusing is the attention on the genetic and somatic variants involved in its progression toward advanced fibrosis and hepatocellular carcinoma. Through Whole-Genome Sequencing WGS of 800 patients with advanced MASLD, 80 liver tissue samples, and 2000 controls, the study aims to:

* Identify rare and structural genetic variants associated with the disease
* Analyze the role of clonal hematopoiesis of indeterminate potential CHIP in MASLD progression.
* Develop polygenic risk scores to improve risk stratification.

genetic and somatic variants involved in its progression toward advanced fibrosis and hepatocellular carcinoma

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Luca Vittorio Carlo Valenti, Doctor

IMA970A is a lyophilized multi-peptide vaccine consisting of 17 individual peptides (active pharmaceutical ingredients) and 2 excipients (Poloxamer 338 and Mannitol). All peptides have been chemically manufactured by well established solid phase peptide synthesis procedures. All peptides are composed of linear, unmodified L- amino acid chains with chain length in the range of 9 to 21 amino acids.

Peptide-based hepatocellular carcinoma vaccine IMA970A

Durvalumab

Montanide ISA™ 51 is a water-in-oil (W/O) emulsion composed of a mineral oil and a surfactant from the mannide monooleate family with immune stimulatory effect .

Montanide (Adjuvant)

The phase Ib portion of the trial explores the incidence of dose-limiting toxicity (DLT) in the quadruple therapeutic regimen. Three weeks after receiving Y90-SIRT, the patients are assigned to one of three dose exploration cohorts: (1) nivolumab 1 mg/kg IV every 3 weeks (Q3W) + ipilimumab 1 mg/kg IV Q3W for up to 4 cycles; (2) nivolumab 1 mg/kg IV Q3W + ipilimumab 2 mg/kg IV Q3W for up to 4 cycles; (3) nivolumab 1 mg/kg IV Q3W + ipilimumab 3 mg/kg IV Q3W for up to 4 cycles. After completion of ipilimumab administration, nivolumab is continued at 480 mg IV every 4 weeks (Q4W) until disease progression, unacceptable toxicity, withdrawal of informed consent, or a maximum treatment duration of two years. Lenvatinib is then administered after discontinuation of ipilimumab, in combination with nivolumab, at a dose of 8 mg (body weight \<60 kg) or 12 mg (body weight \>60 kg) orally once daily (PO QD), taken at a fixed time each day, with or without food.

수술적 절제 전 미세 간세포암에 대한 CT 유도 국소화

진행성 섬유증 및 간세포암으로의 진행에 관여하는 유전적 및 체세포적 변이

펩타이드 기반 간세포암 백신 IMA970A, 두르발루맙, 몬타나이드(보조제)

절제 불가능한 간세포암 환자에서 니볼루맙, 이필리무맙, 렌바티닙과 병용한 트리튬-90 미세구체의 효과